These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 24781536)
1. Cancer charity sees success re-prioritizing industry's shelved compounds. Mullard A Nat Rev Drug Discov; 2014 May; 13(5):319-21. PubMed ID: 24781536 [No Abstract] [Full Text] [Related]
2. An audience with Patrick Vallance. Vallance P Nat Rev Drug Discov; 2010 Nov; 9(11):834. PubMed ID: 21030993 [No Abstract] [Full Text] [Related]
3. Cancer charity is to "borrow" candidate drugs shelved by companies. Mayor S BMJ; 2006 May; 332(7550):1112. PubMed ID: 16690657 [No Abstract] [Full Text] [Related]
4. Biomedicine. Pharma firms push for sharing of cancer trial data. Bhattacharjee Y Science; 2012 Oct; 338(6103):29. PubMed ID: 23042862 [No Abstract] [Full Text] [Related]
5. Cancer charity to re-examine shelved drugs. Mayor S Lancet Oncol; 2006 Jul; 7(7):534. PubMed ID: 16838436 [No Abstract] [Full Text] [Related]
6. What matters most in commercial success: first-in-class or best-in-class? Schulze U; Ringel M Nat Rev Drug Discov; 2013 Jun; 12(6):419-20. PubMed ID: 23722339 [No Abstract] [Full Text] [Related]
7. Advancing the kinase field: new targets and second generation inhibitors. Laufer S; Bajorath J J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234 [No Abstract] [Full Text] [Related]
8. Vas Narasimhan. Narasimhan V; Mullard A Nat Rev Drug Discov; 2016 Jan; 15(1):10-1. PubMed ID: 26718275 [No Abstract] [Full Text] [Related]
10. Picking up the pieces with FBDD or FADD: invest early for future success. Whittaker M Drug Discov Today; 2009 Jul; 14(13-14):623-4. PubMed ID: 19486947 [No Abstract] [Full Text] [Related]
11. Q&A: Bernard Munos. Bender E Nature; 2016 May; 533(7602):S59. PubMed ID: 27167392 [No Abstract] [Full Text] [Related]
12. Collaborative approaches to anticancer drug discovery and development: a Cancer Research UK perspective. Williams RJ; Walker I; Takle AK Drug Discov Today; 2012 Mar; 17(5-6):185-7. PubMed ID: 22314099 [TBL] [Abstract][Full Text] [Related]
13. An audience with...John Reed. Reed J; Mullard A Nat Rev Drug Discov; 2014 Mar; 13(3):170-1. PubMed ID: 24577393 [No Abstract] [Full Text] [Related]
14. Virtual drug discovery with the rise of Chinese CROs. Zhang MQ Drug Discov Today; 2010 Sep; 15(17-18):693-7. PubMed ID: 20685343 [No Abstract] [Full Text] [Related]
15. Could pharma open its drug freezers? Mullard A Nat Rev Drug Discov; 2011 Jun; 10(6):399-400. PubMed ID: 21629278 [No Abstract] [Full Text] [Related]
16. The role of discovery DMPK scientists in industry: where do we go from here? Moriwaki T Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22531680 [No Abstract] [Full Text] [Related]
17. 2011 in reflection. Mullard A Nat Rev Drug Discov; 2012 Jan; 11(1):6-8. PubMed ID: 22212664 [No Abstract] [Full Text] [Related]
18. Menelas Pangalos. Interview by Asher Mullard. Mullard A Nat Rev Drug Discov; 2013 Jun; 12(6):418. PubMed ID: 23722338 [No Abstract] [Full Text] [Related]
19. Ian Tomlinson. Tomlinson I Nat Rev Drug Discov; 2016 Mar; 15(3):154. PubMed ID: 26893183 [No Abstract] [Full Text] [Related]
20. Algeta and Ablynx collaborate to discover and develop targeted cancer therapies. King G Future Med Chem; 2013 Feb; 5(2):123. PubMed ID: 23476969 [No Abstract] [Full Text] [Related] [Next] [New Search]